Skip to main content
SpringerLink
Log in

Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder

Issues and Approaches for Improvement

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 8–10% of school-aged children in the US and for many individuals persists into adolescence and adulthood. Both pharmacological and nonpharmacological (behavioural) therapies are used to treat individuals with ADHD. Treatment with stimulant medications, which include methylphenidate and amphetamine, typically requires multiple daily doses to maintain efficacy. The frequency of treatment, coupled with the importance of timing of doses and the long-term nature of treatment, make noncompliance a particular issue in the treatment of ADHD. Studies report noncompliance rates of 20–65% with stimulant treatment, although there are only limited published studies and these show considerable individual variation. Noncompliance can arise through inadequate supervision of those receiving medication, leading to delayed or missed doses, or through the reluctance of individuals to take medication, which is influenced by a number of factors (e.g. social attitudes, pressures or worries surrounding medication use and the inconvenience of multiple daily doses). Two approaches are likely to increase compliance with stimulant treatment: effective once-daily formulations of medication and improved treatment information. The development of effective once-daily formulations for stimulant treatments removes the need for multiple daily doses, with the associated problems of ensuring adequate treatment supervision and personal privacy. Improved provision of education and information for individuals with ADHD, as well as their families and teachers, should help them address the issues surrounding stimulant medication and allow full participation in the treatment process. Together, these strategies should improve treatment compliance for individuals with ADHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, National Institutes of Health, National Institutes of Mental Health, 1999

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  3. Weiss G, Hectman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 1985; 24: 211–20

    Article  CAS  Google Scholar 

  4. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000; 105: 1158–70

    Article  Google Scholar 

  5. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107(3): E43

    Article  PubMed  CAS  Google Scholar 

  6. Swanson JM, Sergeant JA, Taylor E, et al. Attention-deficit/ hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429–33

    Article  PubMed  CAS  Google Scholar 

  7. Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 2nd ed. New York: The Guilford Press, 1998

    Google Scholar 

  8. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997; 36(8): 1036–45

    Article  PubMed  CAS  Google Scholar 

  9. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86

    Article  Google Scholar 

  10. Swanson JM, McBurnett K, Wigal T, et al. The effect of stimulant medication on ADD children: a “review of reviews”. Except Child 1993; 60: 154–62

    Google Scholar 

  11. Swanson JM, McBurnett K, Christian DL, et al. Stimulant medications and the treatment of children with ADHD. Adv Clin Child Psychol 1995; 17: 265–322

    Google Scholar 

  12. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 1033–44

    Article  Google Scholar 

  13. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention deficit hyperactivity disorder. Rockville (MD): McMaster University, 1999

    Google Scholar 

  14. Pelham WE, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychology 1998; 27(2): 190–205

    Article  Google Scholar 

  15. Greenhill LL, Swanson JM, Vitello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180–7

    Article  PubMed  CAS  Google Scholar 

  16. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 168–79

    Article  PubMed  CAS  Google Scholar 

  17. Swanson JM, Lerner M, Williams L. Letter to the editor: more frequent diagnosis of attention deficit-hyperactivity disorder [letter]. New Engl J Med 1995; 333(14): 944

    Article  PubMed  CAS  Google Scholar 

  18. Class S. Too much attention paid to ADHD? [online]. Available from URL: http://www.inpharm.com/inlelligence/ims020301.html [Accessed 2002 Nov 5]

  19. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41Suppl. 2: 26S–49S

    PubMed  Google Scholar 

  20. Woodworth T. DEA congressional testimony: statement before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families [online]. Available from URL: http://www.dea.gov/pubs/cngrtest/ct051600.htm [Accessed 2000 May 16]

  21. Tomkins CP, Soldin SJ, MacLeod SM, et al. Analysis of pemoline in serum by high performance liquid chromatography: clinical application to optimize treatment of hyperactive children. Ther Drug Monit 1980; 2: 255–60

    Article  PubMed  CAS  Google Scholar 

  22. Collier CP, Soldin SJ, Swanson JM, et al. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity. Clin Pharmacokinet 1985; 10: 269–78

    Article  PubMed  CAS  Google Scholar 

  23. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987; 80: 491–501

    PubMed  Google Scholar 

  24. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990; 86: 226–37

    PubMed  Google Scholar 

  25. Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34(11): 1504–13

    Article  PubMed  Google Scholar 

  26. Sheveli M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1997; 16: 14–6

    Article  Google Scholar 

  27. Swanson JM, Kinsbourne M, Roberts W, et al. A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978; 61:21–9

    PubMed  CAS  Google Scholar 

  28. Chan YM, Swanson JM, Soldin SS, et al. Methylphenidate HC1 (Ritalin) given with or before breakfast. Part II: effects on the plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983; 72: 56–9

    CAS  Google Scholar 

  29. Swanson JM, Sandman CA, Deutsch C, et al. Methylphenidate (Ritalin) given with or before breakfast. Part I: behavioral, cognitive, and electrophysiological effects. Pediatrics 1983; 72: 49–55

    CAS  Google Scholar 

  30. Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10: 2003–11

    Article  PubMed  CAS  Google Scholar 

  31. Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990; 1:7–20

    Article  PubMed  CAS  Google Scholar 

  32. Adesman AR, Morgan AM. Management of stimulant medications in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46(5): 945–63, vii-viii

    Article  PubMed  CAS  Google Scholar 

  33. Szymanski ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. Am Fam Physician 2001; 34: 1355–62

    Google Scholar 

  34. Elia J, Rapoport JL. Ritalin versus dextroamphetamine in ADHD: both should be tried. In: Greenhill LL, Osman BB, editors. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991: 69–74

    Google Scholar 

  35. Efron D, Jarman FC, Barker MJ. “Side effects” of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind crossover trial. Pediatrics 1997; 100(4): 662–6

    Article  PubMed  CAS  Google Scholar 

  36. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001; 11(1): 59–67

    Article  PubMed  CAS  Google Scholar 

  37. Kauffman RE, Smith-Wright D, Reese CA, et al. Medication compliance in hyperactive children. Pediatr Pharmacol (New York) 1981; 1(3): 231–7

    CAS  Google Scholar 

  38. Firestone P. Factors associated with children’s adherence to stimulant medication. Am J Orthopsychiatry 1982; 52(3): 447–57

    Article  PubMed  CAS  Google Scholar 

  39. Sleator EK, Ullman RK, von Neumann A. How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr 1982; 21: 474–9

    Article  CAS  Google Scholar 

  40. Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation. Psychopharmacol Bull 1985; 21(1): 28–36

    PubMed  CAS  Google Scholar 

  41. Brown RT, Borden KA, Wynne ME, et al. Compliance with pharmacological and cognitive treatments for attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1987; 26(4): 521–6

    Article  PubMed  CAS  Google Scholar 

  42. Brown RT, Borden KA, Wynne ME, et al. Patterns of compliance in a treatment program for children with attention deficit disorder. J Compliance Health Care 1988; 3: 23–9

    Google Scholar 

  43. Johnston C, Fine S. Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 1993; 18(6): 717–30

    Article  PubMed  CAS  Google Scholar 

  44. Weiss M, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. Can J Psychiatry 2000; 45: 717–23

    PubMed  CAS  Google Scholar 

  45. Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health 1998; 34(3): 288–92

    Article  PubMed  CAS  Google Scholar 

  46. Safer DJ, Krager JM. The increased rate of stimulant therapy for hyperactive/inattentive students in secondary schools. Pediatrics 1994; 94: 462–4

    PubMed  CAS  Google Scholar 

  47. Reid R, Hertzog M, Snyder M. Educating every teacher, every year: the public schools and parents of children with ADHD. Semin Speech Lang 1996; 17(1): 73–90

    Article  PubMed  CAS  Google Scholar 

  48. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24(2): 302–16

    Article  PubMed  Google Scholar 

  49. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95(1): 68–71

    PubMed  Google Scholar 

  50. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8): 1296–310

    Article  PubMed  CAS  Google Scholar 

  51. Fitzpatrick PA, Klorman R, Brumaghim JT, et al. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(2): 226–34

    Article  PubMed  CAS  Google Scholar 

  52. Greenhill LL, Osman BA, editors. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1999

    Google Scholar 

  53. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999; 66: 295–305

    Article  PubMed  CAS  Google Scholar 

  54. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: proof of concept and proof of product studies. Arch Gen Psychiatry. In press

  55. Swanson J, Gupta S, Williams L, et al. Efficacy of anew pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002; 41:1306–14

    Article  PubMed  Google Scholar 

  56. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta™ methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107(6): E105

    Article  PubMed  CAS  Google Scholar 

  57. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108(4): 883–92

    Article  PubMed  CAS  Google Scholar 

  58. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998; 34: 47–53

    PubMed  CAS  Google Scholar 

  59. Greenhill LL. Once-daily methylphenidate treatment for children with ADHD: the Concerta® Study Group [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

  60. McDaniel D, Greenhill LL. Once-daily methylphenidate formulation for ADHD evaluated in the community [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

  61. Greenhill L. Once-daily methylphenidate modified-release (methylphenidate MR) treatment of attention-deficit/hyperactivity disorder (ADHD): the Methylphenidate MR ADHD Study Group [poster presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2000 Oct 24–29; New York

  62. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: E39

    Article  PubMed  Google Scholar 

  63. Lyseng-Williamson KA, Keating GM. Extended release methylphenidate (Ritalin® LA). Drugs 2002; 62(15): 2251–9

    Article  PubMed  CAS  Google Scholar 

  64. Silva R, Tilker H, Cecil J, et al. Open label, pilot study of dexmethylphenidate in children with ADHD [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

  65. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 104: 1300–11

    Article  PubMed  CAS  Google Scholar 

  66. Swanson JM, Wigal SB, Greenhill L, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 1998; 37(5): 519–26

    Article  PubMed  CAS  Google Scholar 

  67. McCracken JT, Biederman J, Greenhill L, et al. Analog classroom assessment of SLI381 for treatment of ADHD [poster presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2000 Oct 24–29; New York

  68. Successful ADDERALL XR™ launch provides Shire with strong platform for mid to long term growth [press release]. Basingstoke: Shire Pharmaceuticals Group plc, 2002 May 1

  69. Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harvard Rev Psychiatry 2001; 9(5): 223–33

    Article  CAS  Google Scholar 

  70. Cohen NJ, Thompson L. Perceptions and attitudes of hyperactive children and their mothers regarding treatment with methylphenidate. Can J Psychiatry 1982; 27(1): 40–2

    PubMed  CAS  Google Scholar 

  71. Corkum P, Rimer P, Schachar R. Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatry 1999; 44(10): 1043–8

    PubMed  CAS  Google Scholar 

  72. Bennett DS, Power TJ, Rostain AL, et al. Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity. JPediatrPsychol 1996; 21(5): 643–57

    Article  PubMed  CAS  Google Scholar 

  73. Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS Patient Care STDS 2000; 14(3): 155–68

    Article  PubMed  CAS  Google Scholar 

  74. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998; 13(9): 586–93

    Article  PubMed  CAS  Google Scholar 

  75. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109 (6 Pt 2): 554S–9S

    Article  Google Scholar 

  76. Odom SE. Effects of an educational intervention on mothers of male children with attention deficit hyperactivity disorder. J Community Health Nurs 1996; 13(4): 207–20

    Article  PubMed  CAS  Google Scholar 

  77. Greenfield BJ, Senecal J. Recreational multifamily therapy for troubled children. Am J Orthopsychiatry 1995; 65(3): 434–9

    Article  PubMed  CAS  Google Scholar 

  78. Anastopoulos AD, Shelton TL, DuPaul GJ, et al. Parent training for attention-deficit hyperactivity disorder: its impact on parent functioning. J Abnorm Child Psychol 1993; 21(5): 581–96

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Support for the development of new formulations was provided by Alza, Medeva, Novartis, Shire, Celgene Corporation and McNeil Consumer & Specialty Pharmaceuticals. The author acted as a consultant to these pharmaceutical companies and also participated in continuing education and other speaker programs.

Author information

Authors and Affiliations

  1. University of California - Irvine, 19722 MacArthur Boulevard, Irvine, California, 92612, USA

    James Swanson

Authors
  1. James Swanson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Swanson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swanson, J. Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder. Mol Diag Ther 17, 117–131 (2003). https://doi.org/10.2165/00023210-200317020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317020-00004

Keywords

Search

Navigation